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A 65-year-old male had undergone transurethral resection of bladder tumor (TUR-Bt) four times for
recurrent bladder cancer, and each histopathological examination revealed non-invasive urothelial
carcinoma, pTa, G2. To prevent further recurrence, he received eight weekly intravesical instillations of
Bacillus Calmette-Guérin (BCG). Four months after the BCG therapy, he underwent cystoscopy. One
week after the cystoscopy, he developed a painful and swollen left scrotum. Treatment with levofloxacin for
acute epididymitis reduced the scrotal pain initially, but the pain increased and 3 months later, a fistula with
suppurative discharge appeared at the bottom of the scrotum. A smear of the discharge revealed Gaffky 2,
and a culture showed tubercle bacillus. Incisional drainage of the abscess and anti-tuberculosis
chemotherapy for 2 months to treat tuberculous epididymitis was not completely effective. We performed a
left orchiectomy with resection of the infected scrotal skin. Histopathological examination showed
tuberculous epididymitis consisting of a caseating granuloma with epithelioid cells and Langhans giant cells.
He received anti-tuberculosis chemotherapy for 4 months postoperatively and had no sign of recurrence 1
year postoperatively.
(Hinyokika Kiyo 58 : 113-116, 2012)
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現病歴 : 2008年 5月，無症候性肉眼的血尿を主訴に























Fig. 1. A) A fistula discharging pus appeared at the bottom of the scrotum. B) Sagittal T2-weighted
magnetic resonance imaging (MRI) showed a heterogeneous, 5.5-4.2 cm mass (arrow),





MRI 所見 : T2 強調画像にて左精巣上体から皮膚





























Fig. 2. Macroscopic view of the resected specimen.
The infection focus was located in both the
epididymis and scrotum skin (arrow), where-
as the testis was not involved.
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Fig. 3. Histopathologically, the resected tissue re-
vealed tuberculous epididymitis composed of
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Table 1. Summary of the reported cases of tuberculous epididymitis after BCG instillation therapy for bladder cancer









永吉ら5) 陰嚢内容腫大・圧痛 2カ月 抗菌薬（薬剤不明）（抗結核薬と同時に) 0.2カ月 精巣上体 36カ月
諏訪ら4) 陰嚢内容腫大・疼痛 18カ月 抗菌薬（薬剤不明) なし 陰嚢内容 6カ月
岡留ら6) 精巣上体の無痛性腫瘤 4カ月 ― なし 精巣上体 なし
石津ら10) 無痛性陰嚢腫大 5カ月 LVFX 1カ月，陰嚢皮膚自壊 0.5カ月 陰嚢内容・皮膚 1.5カ月
重原ら7) 陰嚢内容腫大・疼痛 0.4カ月 LVFX 1カ月，腫大増強 1カ月，腫大増強
右陰嚢内容，左
精巣上体，皮膚 6 - 9カ月
小泉ら8) 無痛性陰嚢内硬結 1カ月 ―，陰嚢皮膚自壊 なし 陰嚢内容・皮膚 9カ月
水野ら9) 陰嚢内容腫大・疼痛 0.2カ月 ―，陰嚢皮膚自壊 1カ月 陰嚢内容・皮膚 3カ月

































































(SM) また EB を加えた 4 剤併用療法を 2 カ月間行
い，その後 INH および RFP の 2剤併用療法をさらに
4カ月間行う13)．乾燥 BCG 膀胱内用「日本株」の市
販後調査によると BCG 後感染では INH と RFP の 2
剤で治療されていた症例が多かったと報告されている
が，BCG で用いるウシ型結核菌は PZA に対して感受
性がないため，INH，RFP の 2剤に SM か EB を加え
た 3剤併用療法を勧めている14)．本症例では既往歴


























本症例では，BCG 注入療法施行から約 1 年後の
2011年 1 月に膀胱内再発して TUR-Bt を施行してい
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